Pars plana Aurolab aqueous drainage implantation for refractory glaucoma: Outcome of a new modified technique

• Published in: Indian journal of ophthalmology 2022-03, Vol.70 (3), p.839-845
• Main Authors: Kader, Mohideen, Dabke, Shylesh, Shukla, Aakriti, Reddy, Venugopal, Abdul Khadar, Syed, Maheshwari, Devendra, Ramakrishnan, Rengappa
• Format: Article
• Language: English
• Subjects: Acuity; Adult; ahmed glaucoma valve; aurolab aqueous drainage implant; baerveldt glaucoma implant; Care and treatment; Drainage, Surgical; Etiology; Eye; Follow-Up Studies; Glaucoma; Glaucoma - surgery; Glaucoma Drainage Implants; Humans; Implants, Artificial; Intraocular Pressure; Methods; Middle Aged; Original; Patient outcomes; Patients; Prosthesis; Prosthesis Implantation - methods; Retrospective Studies; Surgical drains; Treatment Outcome; tube shunt; Vitrectomy
• ISSN: 0301-4738; 1998-3689
• DOI: 10.4103/ijo.IJO_1791_21

Purpose: To report the outcomes of pars plana insertion of Aurolab aqueous drainage implant (AADI) in adults with refractory glaucoma by the novel technique of making scleral tunnel instead of patch graft to cover the tube to prevent its migration. Methods: A retrospective study was done between April 2016 and April 2018 on patients with ≥12 months of follow-up. The main outcome measure was a surgical failure at 12 months. The failure was defined as intraocular pressure (IOP) >18 mmHg or IOP ≤5 mmHg on two consecutive follow-up visits after 3 months, reoperation for glaucoma, loss of light perception vision, or implant explantation. Alternate definitions of failure including IOP >21 and IOP >15 mmHg were also considered. Results: The study included 32 eyes of 32 patients. The mean age was 46.2 ± 17.5 years. The most common etiology is traumatic glaucoma (12 eyes, 37.5%). The mean preoperative IOP and anti-glaucoma medications were 43.3 ± 10.3 and 3.4 ± 0.5 mmHg, respectively; both the parameters at the final follow-up were reduced to 15.2 ± 8.1 and 1.6 ± 0.5 mmHg. The Kaplan-Meier survival estimates demonstrated that the cumulative probability of failure was 15.6% (95% CI; 6.8-33.5%) at 3 months, 18.7% (95% CI; 8.9-37.0%) at 6 months, and 25.0% (95% CI; 13.4-43.8%) at 12 months. Conclusion: Pars plana AADI implantation with a newer modification technique is a useful procedure in reducing IOP and the number of anti-glaucoma medications in the eyes with refractory glaucoma. The visual acuity may be stabilized with the concurrent treatment of posterior segment pathology.